Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paltusotine in Acromegaly (ACROBAT Advance)
NCT04261712Phase 2Terminated
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of paltusotine in acromegaly, sponsored by Crinetics Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at 316 weeks. Started Jan 2020; status: terminated.
02
Drugs
paltusotine
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT04261712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261712.